Summit Therapeutics (SMMT) Cash from Investing Activities (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Cash from Investing Activities data on file, last reported at $222.9 million in Q2 2026.

• Quarterly Cash from Investing Activities rose 47.8% year-over-year to $222.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$262.6 million (down 191.88% YoY) and the FY2025 annual result came in at -$174.3 million, up 15.11% from the prior year.
• Cash from Investing Activities advanced to $222.9 million in Q2 2026, from -$238000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $222.9 million in Q2 2026 to a low of -$645.1 million in Q1 2023.
• A 5-year average of -$41.4 million and a median of -$30500.0 in 2022 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 605580.0% in 2023, down 178587.81% in 2023.
• Tracing SMMT's Cash from Investing Activities over 5 years: stood at $10000.0 in 2022, then jumped by 605580.0% to $60.6 million in 2023, then soared by 37.83% to $83.5 million in 2024, then tumbled by 681.15% to -$485.2 million in 2025, then soared by 145.94% to $222.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $222.9 million (Q2 2026), -$238000.0 (Q1 2026), and -$485.2 million (Q4 2025), per Business Quant data.